It could be available within months. Food and Drug Administration advisers on Thursday unanimously supported the first government approval of a medication made from cannabis, paving the way for agency clearance by the end of June. The drug, Epidiolex, would be administered in a syrup form and is made from a purified ingredient in cannabis called cannabidiol, or CBD. It is intended to treat severe seizures in children caused by rare forms of epilepsy called Lennox-Gastaut and Dravet syndromes. Most patients with those diseases have uncontrolled daily seizures despite treatment, putting them at high risk for developmental disabilities, serious injury and premature death, the FDA staff said in background materials released this week. The unanimous support of the 13-member FDA advisory committee seemed assured after agency staff members gave the drug a positive review, saying that clinical trials showed that it was effective at reducing seizures and that side effects, including possible liver complications, could be managed. The First Cannabis-Based Drug in The US Has Been Recommended by FDA Panel

thumbnail courtesy of